3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase 1/2
1
Phase 1
1
Status
Completed
7
Active not recruiting
4
Recruiting
3
Sponsor Class
INDUSTRY
4
Study Type
Interventional
4
Sponsor
Cancer Type
Breast
4
Thoracic
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Conditions
Breast Neoplasms
4
Neoplasm Metastasis
3
Neoplasms by Site
2
Neoplasms
2
Breast Diseases
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Skin Diseases
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Biliary Tract Neoplasms
1
Interventions
Paclitaxel
62
Letrozole
55
Fulvestrant
55
Trastuzumab
50
palbociclib
41
pembrolizumab
37
Cyclophosphamide
37
Carboplatin
37
Anastrozole
37
pertuzumab
35
exemestane
25
Tamoxifen
24
Capecitabine
24
ribociclib
23
abemaciclib
23
Radiotherapy
21
Docetaxel
21
olaparib
20
Doxorubicin
20
Magnetic Resonance Spectroscopy
19
trastuzumab deruxtecan
17
Surveys and Questionnaires
17
durvalumab
16
Epirubicin
16
Specimen Handling
14
Exercise
14
130-nm albumin-bound paclitaxel
14
Taxes
13
Alpelisib
13
Goserelin
12
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
4 trials
Recent
Start date
Enrollment
Active not recruiting
×
Breast Neoplasms
×
AZD9833
×
Clear all
NCT03616587
2026-04-30
SERENA-1
AstraZeneca
Phase 1
Active not recruiting
396 enrolled
NCT04964934
2026-04-21
SERENA-6
AstraZeneca
Phase 3
Active not recruiting
315 enrolled
NCT04644068
2026-02-19
PETRA
AstraZeneca
Phase 1/2
Active not recruiting
702 enrolled
NCT04711252
2025-10-14
SERENA-4
AstraZeneca
Phase 3
Active not recruiting
1,370 enrolled